4-Antibody AG closes CHF 6 Million Series A financing and appoints Sijmen de Vries as CEO

23-Aug-2006

4-Antibody announced the closing of a CHF 6 million Series A financing and the appointment of Sijmen de Vries MD, MBA as its new CEO.

The Series A financing was provided by a consortium of existing investors including Biomedinvest AG (CH), Grazia Equity (D), Life Science Partners (NL) and Mulligan Biocapital (D). Proceeds will be used to develop internal pipeline projects initially to pre-clinical proof of concept and establish licensing partnerships with biotech and pharma partners.

Sijmen joins 4- Antibody from Morphochem AG (Munich, Germany), where he was CEO and, after successfully re-focusing the business on antibiotic development and steering its lead hospital antibiotic through pre-clinical development, he merged the company with Biovertis AG. Previous to that, he held various senior management positions at Novartis Pharma AG and SmithKline Beecham. Dr de Vries succeeds Dr Ulf Grawunder, who as co-founder of the company successfully led the company through its initial growth phases and continues to serve the company as its CSO.

Other news from the department people

Most read news

More news from our other portals

So close that even
molecules turn red...